
Diffuse Large B-Cell Lymphoma Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Mehdi Hamadani, MD, discusses an analysis evaluating the role of autologous transplant in relapsed DLBCL with newer therapies, specifically CAR T-cells.
View MoreDr Neelapu talks about early findings from the ALPHA study which suggest that ALLO-501 and ALLO-647 are safe and may be effective in LBCL.
View MoreNilanjan Ghosh, MD, reviews results from a pilot study of lisocabtagene maraleucel for the treatment of relapsed large cell lymphomas.
View MoreDr Torka talks about the outcomes of patients with limited-stage, aggressive large B-cell lymphoma and high-risk cytogenetics.
View MoreSarah Rutherford, MD, discusses how postinduction bone marrow biopsy histology minimally affects radiographically-defined responses in patients with FL and DLBCL.
View MoreSarah Rutherford, MD, discusses the results from a phase 1 study, which evaluated the combination of venetoclax and DA-EPOCH-R for aggressive B-cell lymphomas.
View MoreWendy Osborne, MBBS (Hons), MRCP, FRCPath, discusses results from the phase 1 Alexander study, which evaluated AUTO3 plus pembrolizumab in relapsed/refractory DLBCL.
View MoreJohn Kuruvilla, MD, FRCPC, discusses the results from the phase 3 KEYNOTE‑204 trial, which compared pembrolizumab against brentuximab vedotin in relapsed/refractory classical Hodgkin lymphoma.
View MoreCharles Herbaux, MD, MSc, discusses results from the phase 2 GATA study, which evaluated the efficacy and safety of obinutuzumab plus atezolizumab and venetoclax for relapsed/refractory DLBCL.
View More